Skip to main content

Table 2 Linear regression analysis investigating factors associated with first-phase HIV RNA half-life decay

From: An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy

  Univariate analysis Multivariate analysis
Change (95% CI)a p-value Change (95% CI)a p-value
Maternal age, per 1-year higher 0.02 (− 0.01, 0.05) 0.24   
Black African/Caribbean ethnicity − 0.13 (− 0.61, 0.35) 0.17   
HIV acquired via heterosexual intercourse 1.08 (− 0.34, 2.51) 0.14   
Previous cART use − 0.08 (− 0.45, 0.29) 0.67   
Baseline CD4+ T-cell count, per 10 cells/µL increase 0.01 (0.00, 0.02) 0.003 0.00 (− 0.01, 0.01) 0.47
Baseline plasma HIV RNA, per 1 log10 copies/mL higher − 0.71 (− 0.97, − 0.46) < 0.001 − 0.611 (− 0.918, − 0.305) < 0.001
Gestational age when cART was started, per 1-week higher − 0.02 (− 0.05, 0.01) 0.21   
Antiretroviral third agent class
 PI 0.34 (− 0.04, 0.72) 0.08   
 NNRTI − 0.27 (− 0.74, 0.21) 0.27   
 INSTI − 0.84 (− 1.46, − 0.23) 0.007 − 0.365 (− 0.982, 0.251) 0.24
  1. CI confidence interval, cART combination antiretroviral treatment, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor
  2. aChange (95% CI) reflects the associated impact of each independent variable in the model on the first-phase HIV RNA half-life decay
\